Latest news with #HilleVax
Globe and Mail
3 days ago
- Business
- Globe and Mail
Shareholder Alert: The Ademi Firm Investigates Whether HilleVax, Inc. Is Obtaining a Fair Price for Its Public Shareholders
The Ademi Firm is investigating HilleVax (NASDAQ: HLVX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty Corporation . Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of HilleVax will receive $1.95 per share in cash plus contingent value rights. The CVR provides potential additional payments based on HilleVax's remaining cash above $102.95 million, savings from Boston office lease obligations, and proceeds from any sale of the company's norovirus vaccine programs within specified timeframes. HilleVax insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for HilleVax by imposing a significant penalty if HilleVax accepts a competing bid. We are investigating the conduct of the HilleVax board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Business Wire
3 days ago
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether HilleVax, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating HilleVax (NASDAQ: HLVX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty Corporation. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of HilleVax will receive $1.95 per share in cash plus contingent value rights. The CVR provides potential additional payments based on HilleVax's remaining cash above $102.95 million, savings from Boston office lease obligations, and proceeds from any sale of the company's norovirus vaccine programs within specified timeframes. HilleVax insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for HilleVax by imposing a significant penalty if HilleVax accepts a competing bid. We are investigating the conduct of the HilleVax board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Yahoo
7 days ago
- Business
- Yahoo
Xoma strikes deals to buy struggling biotechs HilleVax, Lava
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Xoma Royalty Corporation on Monday announced a pair of agreements to acquire biotechnology companies HilleVax and Lava Therapeutics, which have both struggled since going public several years ago. Xoma offered $1.95 per HilleVax share to investors in that company, as well as rights to any additional cash HilleVax holds above roughly $103 million at deal closing, a portion of any savings on a Boston building lease and 90% of any proceeds from the sale of HilleVax's norovirus vaccine programs. HilleVax went public in 2022 with plans to develop a vaccine for moderate or severe acute gastroenteritis. Co-founded by Tadataka Yamada, a former Takeda Pharmaceutical executive, and Frazier Life Sciences, it raked in $200 million to progress a vaccine it had licensed from the Japanese pharmaceutical company. HilleVax's value has plummeted over the past two years, however, after a mid-stage trial showed its vaccine was ineffective, causing the company to halt development of its lead program in infants, cut 40% of its staff and seek strategic alternatives. For Lava, Xoma is paying at least $1.16 — and potentially up to $0.08 more — per share of the Dutch company. It is also offering a contingent value right worth 75% of net proceeds from its partnered programs and any sale of its wholly owned pipeline assets. 'We believe the structure of this transaction has the potential to benefit both Lava and Xoma Royalty shareholders over time,' Xoma CEO Owen Hughes said in a statement on the Lava deal. Lava makes a type of bispecific antibody for cancer called gamma delta T cell engagers. It has a pair of programs in development with Pfizer and Johnson & Johnson, the former of which is for solid tumors while the latter is focused on blood cancers. The Netherlands-based biotech previously licensed out a preclinical prospect to Seagen. In February, the company announced it would lay off 30% of its staff after disappointing results from a study of its lead program. Lava CEO Steve Hurly said at the time that, 'with only one product in clinical development and an early-stage pipeline,' it was 'appropriate to investigate strategic opportunities.' Both HilleVax and Lava are examples of 'biotech zombies' — companies that, due to research or other setbacks, trade at market capitalizations below their cash holdings. In recent quarters, these companies have come under pressure to dissolve and return that cash to shareholders, while others have chosen reverse mergers or buyout deals like the two struck by Xoma Monday. Concentra Biosciences has emerged as a major player in the acquisition of these distressed biotechs, striking several deals this year to buy Cargo Therapeutics, Elevation Oncology and Allakos. Other firms are taking note. Last week, KKR said it acquired a majority ownership stake in HealthCare Royalty Partners, which has pursued a similar business model to Xoma. And earlier this year, Alis Biosciences launched with a new fund with the goal of freeing 'trapped' capital on balance sheets in biotech. Venture investors are working on ways to support struggling startups, too. On Monday, OrbiMed, a prolific equity funder of new biotechs, announced a $1.86 billion fund for 'non-dilutive credit and royalty-based financing.' Recommended Reading Replay reveals second gene therapy spinout, debuting new biotech Telaria Connectez-vous pour accéder à votre portefeuille
Globe and Mail
7 days ago
- Business
- Globe and Mail
HLVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of HilleVax, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of HilleVax, Inc. (NASDAQ: HLVX) to XOMA Royalty Corporation is fair to HilleVax shareholders. Under the terms of the proposed transaction, HilleVax stockholders will receive $1.95 in cash per share, plus one non-transferable contingent value right, representing the right to receive additional payments under certain conditions. Halper Sadeh encourages HilleVax shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ or zhalper@ The investigation concerns whether HilleVax and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for HilleVax shareholders; (2) determine whether XOMA is underpaying for HilleVax; and (3) disclose all material information necessary for HilleVax shareholders to adequately assess and value the merger consideration. On behalf of HilleVax shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Yahoo
17-04-2025
- Business
- Yahoo
Frazier Life Sciences Appoints Aditya Kohli to Partner
PALO ALTO, Calif., April 17, 2025--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ: HLVX, IPO in 2022), Phathom Pharmaceuticals (NASDAQ: PHAT, IPO in 2019), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to see him step into this next chapter at the firm as Partner," said Jamie Topper, M.D., Ph.D., Managing Partner at FLS. "With over 10 years of industry experience, Aditya will lend his leadership experience and extensive operating knowledge as we back and build the next generation of biotech companies." As Partner, Dr. Kohli will continue focusing on company creation while also expanding his role to include broader investment responsibilities and shaping FLS's investment strategy. "Frazier Life Sciences is an incredibly supportive team with a long-term mindset, which makes all the difference when it comes to making thoughtful investments and providing enduring support to our portfolio companies," said Dr. Kohli. "I'm excited to help lead our company creation efforts for innovative biotechs delivering novel therapeutics." Prior to joining FLS, Dr. Kohli was an Engagement Manager with McKinsey & Company. He earned his Ph.D. from the UC Berkeley and UC San Francisco joint graduate program in bioengineering and holds B.S. and degrees in biological engineering from the Massachusetts Institute of Technology (MIT). About Frazier Life Sciences Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including Venture Funds focusing on company creation and private companies and the long-only Public Funds focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by FLS, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals in biopharmaceuticals, primarily located in Palo Alto, Calif. (headquarters), San Diego, Seattle, Boston, New York, and London. For more information about Frazier Life Sciences, please visit and follow us on LinkedIn. View source version on Contacts For media inquiries, please contact: Ailsa Dalgliesh, of Investor Relations ailsa@ Sign in to access your portfolio
